–
–
–
–
–>
Celltrion’s novel coronavirus infection (Corona 19) antibody treatment,’Rekironaju’, was reported to have been supplied to four medical institutions on the 17th, a total of 151 bottles (vials).
The Central Defense Response Headquarters (Bang Dae-bon) announced at the Corona 19 regular briefing that the supply status as of 0 o’clock on the 18th was compiled in this way.
Rekironaju, which has been supplied free to medical institutions nationwide from the previous day, is an intravenous drug with a dose of 960mg per bottle. 40 mg per 1 kg of patient’s body weight is used.
The targets for administration of Rekirona, approved by the Ministry of Food and Drug Safety, are patients with mild and moderate symptoms in high-risk groups (the elderly or those with underlying diseases). In the results of phase 2 clinical trials submitted to the Ministry of Food and Drug Safety, patients with general mild symptoms were excluded from administration due to insufficient clinical data.
Remdesivir, a drug that was approved for use in Korea before Rekkirona, was administered to a total of 4522 patients in 121 hospitals by the day.
On the other hand, from the 8th, Bang Dae-bon has conducted a total of 10 cases, including 5 mutant viruses originating in the UK and 5 mutant viruses originating in South Africa. He said that the sale of mutant stocks was done.
In addition, since February of last year, including this, 832 viruses and nucleic acids have been distributed to a total of 208 institutions.
An official from Bang Dae-bon said, “We plan to continue to distribute the virus so that related ministries and research institutions can use it for the development of vaccines and treatments for the corona 19 virus, and the development of diagnostic drugs.”
–
©’Five-language global economic newspaper’ Ajou Economy. Prohibition of unauthorized reproduction and redistribution
.
Related
